SPY771.54+0.02%QQQ744.95+0.06%BTC/USD83,717.00−0.79%DIA517.45−0.01%GLD392.95−0.12%TLT79.30−0.03%
Benzinga

Protalix BioTherapeutics Inc (PLX) Stock Price, Quote, News & History

PLXAMEX
Trade with Public
Trade with Public
$2.72
-0.03-1.09%
At close: Sep 25, 5:00 PM EST
$2.72
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Protalix BioTherapeutics (PLX) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$2.76
Close
$2.72
Volume / Avg.
386.02K / 708.33K
Day Range
$2.70 - $2.78
52 Wk Range
1.60 - 3.19
Market Cap
$219.15M
P/E Ratio
11.96
Dividend Yield
-
Exchange
AMEX
RSI
56
Short Interest
3.72%
Days to Cover
3.82

Recent Protalix BioTherapeutics, Inc. News

Why Is Protalix BioTherapeutics Stock Falling On Friday?

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.
Vandana Singh

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
Vandana Singh

Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Lisa Levin

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult 
Vandana Singh

Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil

Nabaparna Bhattacharya
40%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
9.92M
Investing Cash Flow (TTM)
-1.03M
Financing Cash Flow (TTM)
296.00K
Free Cash Flow (TTM)
7.67M
Capital Expenditure (TTM)
-2.26M
Net Change in Cash (TTM)
9.19M

Analyst Trends and Forecast

1
Sep
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$190.12M
PE Ratio (TTM)
11.96
PE Ratio (FWD)
54.95
PEG Ratio (TTM)
-
PS Ratio (TTM)
2.77
PB Ratio (TTM)
3.10
Earnings Yield % (TTM)
8.36%
Earnings Yield % (FWD)
1.82%
EV / EBITDA (TTM)
7.24
Price / EBITDA (TTM)
8.50
Price / Free Cash Flow (TTM)
29.09
Book Value / Share
$0.89

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$27.42M
Debt to Equity
0.13
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$2.76
Close
$2.72
Volume / Avg.
386.02K / 708.33K
Day Range
$2.70 - $2.78
52 Wk Range
1.60 - 3.19
Market Cap
$219.15M
P/E Ratio
11.96
Dividend Yield
-
Exchange
AMEX
RSI
56
Short Interest
3.72%
Days to Cover
3.82

About

Sector
Health Care
Industry
Biotechnology
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-ba...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Protalix BioTherapeutics (PLX) stock?

A

You can purchase shares of Protalix BioTherapeutics (AMEX:PLX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Protalix BioTherapeutics (PLX) competitors?

Q

What is the forecast, or price target, for Protalix BioTherapeutics (PLX) stock?

A

Protalix BioTherapeutics has a consensus price target of $12.00.

Q

What is the current price for Protalix BioTherapeutics (PLX)?

A

The stock price for Protalix BioTherapeutics (AMEX: PLX) is $2.72 last updated September 25, 2026 at 4:00 PM EDT.

Q

Does Protalix BioTherapeutics (PLX) pay a dividend?

A

There are no upcoming dividends for Protalix BioTherapeutics.

Q

When is Protalix BioTherapeutics (AMEX:PLX) reporting earnings?

A

Protalix BioTherapeutics does not have any upcoming earnings scheduled.

Q

Is Protalix BioTherapeutics (PLX) going to split?

A

There is no upcoming split for Protalix BioTherapeutics.

Q

What sector and industry does Protalix BioTherapeutics (PLX) operate in?

A

Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved